MX2024005766A - Compuesto de imidazo[4,5-b]piridina cristalina, composiciones farmacéuticas y su uso en el tratamiento de condiciones médicas. - Google Patents
Compuesto de imidazo[4,5-b]piridina cristalina, composiciones farmacéuticas y su uso en el tratamiento de condiciones médicas.Info
- Publication number
- MX2024005766A MX2024005766A MX2024005766A MX2024005766A MX2024005766A MX 2024005766 A MX2024005766 A MX 2024005766A MX 2024005766 A MX2024005766 A MX 2024005766A MX 2024005766 A MX2024005766 A MX 2024005766A MX 2024005766 A MX2024005766 A MX 2024005766A
- Authority
- MX
- Mexico
- Prior art keywords
- imidazo
- crystalline
- pharmaceutical compositions
- pyridine compound
- treating medical
- Prior art date
Links
- -1 PYRIDINE COMPOUND Chemical class 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 title abstract 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 title abstract 2
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 102000005937 Tropomyosin Human genes 0.000 abstract 1
- 108010030743 Tropomyosin Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21207942.0A EP4180428A1 (en) | 2021-11-12 | 2021-11-12 | Crystalline imidazo[4,5-b]pyridine compound, pharmaceutical compositions, and their use in treating medical conditions |
| PCT/US2022/049695 WO2023086564A1 (en) | 2021-11-12 | 2022-11-11 | Crystalline imidazo[4,5-b]pyridine compound, pharmaceutical compositions, and their use in treating medical conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024005766A true MX2024005766A (es) | 2024-07-29 |
Family
ID=78617277
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024005766A MX2024005766A (es) | 2021-11-12 | 2022-11-11 | Compuesto de imidazo[4,5-b]piridina cristalina, composiciones farmacéuticas y su uso en el tratamiento de condiciones médicas. |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US11814383B2 (https=) |
| EP (2) | EP4180428A1 (https=) |
| JP (1) | JP2024543413A (https=) |
| CN (1) | CN118843624A (https=) |
| AU (1) | AU2022387516A1 (https=) |
| CA (1) | CA3237156A1 (https=) |
| IL (1) | IL312625A (https=) |
| MX (1) | MX2024005766A (https=) |
| TW (1) | TW202334143A (https=) |
| WO (1) | WO2023086564A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI731317B (zh) * | 2013-12-10 | 2021-06-21 | 美商健臻公司 | 原肌球蛋白相關之激酶（ｔｒｋ）抑制劑 |
| EP4180428A1 (en) | 2021-11-12 | 2023-05-17 | Genzyme Corporation | Crystalline imidazo[4,5-b]pyridine compound, pharmaceutical compositions, and their use in treating medical conditions |
| CN121464134A (zh) * | 2023-05-17 | 2026-02-03 | 中枢疗法公司 | 咪唑并[4,5-b]吡啶化合物的颗粒、药物组合物及其在治疗医学病症中的用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI731317B (zh) | 2013-12-10 | 2021-06-21 | 美商健臻公司 | 原肌球蛋白相關之激酶（ｔｒｋ）抑制劑 |
| EA201791336A1 (ru) | 2014-12-18 | 2017-10-31 | Джензим Корпорейшн | Фармацевтические составы на основе ингибиторов тропомиозин-родственных киназ (trk) |
| WO2019084285A1 (en) | 2017-10-26 | 2019-05-02 | Qian Zhao | FORMULATIONS OF A MACROCYCLIC TRK KINASE INHIBITOR |
| WO2019191659A1 (en) | 2018-03-29 | 2019-10-03 | Loxo Oncology, Inc. | Treatment of trk-associated cancers |
| JP7472103B2 (ja) * | 2018-08-22 | 2024-04-22 | クルゲン（シャンハイ），インク． | トロポミオシン受容体キナーゼ（ｔｒｋ）分解化合物とその使用方法 |
| EP4110772A4 (en) | 2020-02-26 | 2024-04-03 | Cullgen (Shanghai), Inc. | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE |
| EP4180428A1 (en) | 2021-11-12 | 2023-05-17 | Genzyme Corporation | Crystalline imidazo[4,5-b]pyridine compound, pharmaceutical compositions, and their use in treating medical conditions |
-
2021
- 2021-11-12 EP EP21207942.0A patent/EP4180428A1/en not_active Withdrawn
-
2022
- 2022-11-11 IL IL312625A patent/IL312625A/en unknown
- 2022-11-11 EP EP22893662.1A patent/EP4430043A4/en active Pending
- 2022-11-11 US US17/985,531 patent/US11814383B2/en active Active
- 2022-11-11 JP JP2024527604A patent/JP2024543413A/ja active Pending
- 2022-11-11 CA CA3237156A patent/CA3237156A1/en active Pending
- 2022-11-11 CN CN202280087913.4A patent/CN118843624A/zh active Pending
- 2022-11-11 AU AU2022387516A patent/AU2022387516A1/en active Pending
- 2022-11-11 MX MX2024005766A patent/MX2024005766A/es unknown
- 2022-11-11 WO PCT/US2022/049695 patent/WO2023086564A1/en not_active Ceased
- 2022-11-11 TW TW111143263A patent/TW202334143A/zh unknown
-
2023
- 2023-11-09 US US18/505,713 patent/US12291528B2/en active Active
-
2025
- 2025-04-22 US US19/185,943 patent/US20250250274A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW202334143A (zh) | 2023-09-01 |
| JP2024543413A (ja) | 2024-11-21 |
| US20250250274A1 (en) | 2025-08-07 |
| IL312625A (en) | 2024-07-01 |
| WO2023086564A1 (en) | 2023-05-19 |
| CN118843624A (zh) | 2024-10-25 |
| US11814383B2 (en) | 2023-11-14 |
| EP4180428A1 (en) | 2023-05-17 |
| AU2022387516A1 (en) | 2024-05-23 |
| US12291528B2 (en) | 2025-05-06 |
| EP4430043A1 (en) | 2024-09-18 |
| EP4430043A4 (en) | 2025-11-05 |
| US20230151008A1 (en) | 2023-05-18 |
| US20240150352A1 (en) | 2024-05-09 |
| CA3237156A1 (en) | 2023-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20220537A (es) | [1,3]DIAZINO[5,4-d]PIRIMIDINAS COMO INHIBIDORES DE HER2 | |
| MX2024005766A (es) | Compuesto de imidazo[4,5-b]piridina cristalina, composiciones farmacéuticas y su uso en el tratamiento de condiciones médicas. | |
| GEAP202416515A (en) | Quinoline compounds as inhibitors of kras | |
| MX2024000357A (es) | Compuestos triciclicos como inhibidores de homologo de oncogen viral de sarcoma de rata kirsten (kras). | |
| PH12021550187A1 (en) | Pyrrolopyrimidine itk inhibitors | |
| PH12022552739A1 (en) | Fused tricyclic kras inhibitors | |
| MX2021007970A (es) | Derivado de 6-oxo-1,6-dihidropiridazina, metodo de preparacion del mismo y uso medico del mismo. | |
| MX2023005636A (es) | Inhibidores de bcl6 derivados de bencimidazolona. | |
| EP4548918A3 (en) | Tricyclic compounds as inhibitors of kras | |
| MX2023003564A (es) | Compuestos y su uso en el tratamiento del cancer. | |
| NO20010743L (no) | Antivirale indoloksoacetyl-piperazin-derivater | |
| WO2016118951A3 (en) | Heterocyclic itk inhibitors for treating inflammation and cancer | |
| MX2010014233A (es) | Compuestos quimicos 251. | |
| TN2009000224A1 (en) | Inhibitors of akt activity | |
| MX2009004745A (es) | Derivados de 1,2,3-triazol como inhibidores del receptor sigma. | |
| EP4371562A3 (en) | 2-quinolone derived inhibitors of bcl6 | |
| TW200714604A (en) | Substituted heterocycles and the uses thereof | |
| WO2007007919A3 (en) | Heterocyclic janus kinase 3 inhibitors | |
| BRPI0514736A (pt) | inibidores do receptor sigma | |
| ZA202203520B (en) | [1,4]oxazepino[2,3-c]quinolinone derivatives as bcl6 inhibitors | |
| PH12021553248A1 (en) | Heterocyclic monoacylglycerol lipase (magl) inhibitors | |
| WO2009022185A3 (en) | 6, 6-fused heterocycles, their pharmaceutical compositions and methos of use | |
| PH12022551623A1 (en) | Substituted pyrazolo-pyrimidines and uses thereof | |
| MY133995A (en) | 6-phenylpyrrolopyrimidinedione derivatives | |
| MX2023010711A (es) | Fenalquilaminas y métodos de preparación y uso de las mismas. |